The effect size for a difference in ADAMTS13 between other thrombotic diseases and healthy controls was calculated from a study of myocardial infarction and stroke (Andersson). An estimated 142 individuals would be required for a small-medium effect size at a power of 80% (supplementary figure S7a). However, to establish what effect size is appropriate for CTEPH a pilot study was performed in 2016 to refine the sample size estimates. ADAMTS13 plasma antigen levels were measured in 94 CTEPH patients and 29 healthy controls. This confirmed a larger effect size between CTEPH and healthy controls than had previously been reported for other thrombotic diseases. Consequently, an estimated 30 individuals (per group) would be required for a large effect size in ADAMTS13 with 80% power (supplementary figure S7b). Furthermore, as CTEPH, CTED and IPAH are rare diseases with limited sample numbers available, the study was powered for larger effect sizes.
controls and disease comparators (CTED, IPAH and PE). However, given the known demographic differences across these disease groups and limited sample availability for rare diseases, it was not possible to fully propensity match. Therefore, healthy controls and disease comparators were selected for the closest possible age-and sex-matching to the CTEPH group. The closest matched (age and sex) CTED patients (n=35) from Royal Papworth Hospital with available bio-banked samples were selected. The definition used for CTED patients has been previously described [1] . IPAH patients (n=30) from Royal Papworth Hospital were also selected for the closest age/sex matching and additionally all IPAH patients were matched for anticoagulation therapy usage but had not had a venous thromboembolism. The PE group were sampled from a specialist PE follow-up service (Hammersmith Hospital) at a median of 220 (interquartile range (IQR) 218) days following an acute PE. All consecutive patients (n=28) with bio-banked samples available (November 2013 to October 2014) were included in the study.
As the CTEPH, healthy control and disease comparator groups could not be fully matched for age and sex, these variables were included in multivariable linear models described in the statistical analysis section.
ADAMTS13 and VWF plasma concentrations
Plasma ethylenediaminetetraacetic acid (EDTA) samples were used to measure ADAMTS13 and VWF antigen (Ag) levels by enzyme-linked immunosorbent assays (ELISA). Normal human control plasma (Technoclone, Vienna, Austria) with known concentrations of ADAMTS13 and VWF was used as the reference [2] .
ADAMTS13
ADAMTS13 plasma antigen levels were quantified using a polyclonal rabbit anti-ADAMTS13 antibody (5μg/mL, anti-TSP2-4 depleted) as previously described [2, 3] . The antibody was immobilised in 96-well microplates (Nunc, Rochester, USA) in 50mM carbonate buffer, pH 9.6 at 4°C overnight. Washes were performed with phosphate buffered saline (PBS) + 0.1% Tween-20 (PBST), and this was repeated between each step. Wells were blocked with 1% bovine serum albumin (BSA) in PBS for 1 hour. Plasma samples were diluted 1:20 using 1% BSA in PBS and added to the wells in duplicate for 2 hours. A standard curve of 0-126 ng/mL was made with normal human control plasma (NHP) (Technoclone, Vienna, Austria). Bound ADAMTS13 was detected with biotinylated anti-TSP2-4 polyclonal antibody for 2 hours followed by incubation of wells with streptavidin-horseradish peroxidase (HRP) (GE Healthcare, UK) for 1 hour. Plates were developed with a peroxidase substrate (o-phenylenediamine dihydrochloride (OPD); Sigma-Aldrich, Darmstadt, Germany) for 5 minutes and the reaction was stopped with 65μL/well of 2.5M H2SO. Absorbance was read at 492nm (FLUOstar Omega plate reader, BMG Labtech). ADAMTS13 concentrations were obtained by interpolating from the standards fitted with a four-parameter logistic curve. The intra-and inter-assay coefficients of variation were 8 and 12% respectively.
To enable a comparison with other published thrombotic diseases, each ADAMTS13 plasma antigen level was divided by the median of the healthy control group and expressed as a percentage. The CTEPH group was then divided into quartiles of the ADAMTS13 distribution of the healthy control group. The odds ratios for a combination of ADAMTS13 and VWF antigen levels. The quartile thresholds were used to stratify CTEPH patients and healthy controls into groups using a combination of ADAMTS13 and VWF levels. Odds ratios for the different groups were then assessed using logistic regression adjusted for age, sex, ethnicity and experimental batch.
VWF
VWF plasma antigen levels were quantified in a similar well-described manner using a polyclonal rabbit anti-VWF antibody (3.1 μg/mL; Dako, Santa Clara, USA) [3] . After overnight antibody immobilisation and washes, wells were blocked with 1% BSA in PBST for 1 hour. Plasma samples were diluted 1:400 in PBST 1% BSA and a standard curve of 0-125 ng/L was made with NHP. VWF was detected with 1.1μg/mL Polyclonal Rabbit Anti-Human VWF/HRP (Dako) followed by plate development with OPD for 3 minutes. The intra-and inter-assay coefficients of variation were 5 and 8% respectively. The ADAMTS13 and VWF ELISAs were performed for all groups in 2016 (batch1) and additional CTEPH samples (n=115) were included in 2017 (batch2). Batch variation in ADAMTS13 and VWF was adjusted using replicate samples (ADAMTS13: n=24, VWF: n=12) and additionally batch was included as a covariate in multivariable linear regression models.
ADAMTS13 activity, D-dimer, anti-ADAMTS13 autoantibodies and VWF multimeric size
Additional experiments were performed on a subset of the CTEPH (n=23) and healthy control (n=14) groups to identify potential mechanisms for any dysregulation of the ADAMTS13-VWF axis. Plasma lithium heparin samples were used to measure ADAMTS13 activity, D-dimer concentrations and anti-ADAMTS13 autoantibodies. The CTEPH sample subset were those with the lowest ADAMTS13 antigen levels (below the first quartile of the CTEPH group) and the healthy controls were those with ADAMTS13
antigen levels closest to the median of the control group. An estimate of VWF multimeric size was made by measuring VWF collagen binding (VWF:CBA) and comparing this with VWF antigen levels in the CTEPH (n=21) samples with the highest VWF antigen concentrations (above the third quartile of the CTEPH group) and the same healthy control subset.
ADAMTS13 Activity
ADAMTS13 activity was measured with a fluorescence resonance energy transfer (FRETS) assay using a short synthetic VWF peptide (VWF73: PeptaNova, Sandhausen, Germany) containing the ADAMTS13 cleavage site for VWF [4] . Plasma samples and NHP were diluted to 1:10 in reaction buffer (5 mM Bis-Tris, 25 mM CaCl2 and 0.005% Tween-20 at pH 6.0) in 96-well plates (Nunc, Rochester, USA). FRETS-VWF73 substrate (an equal volume of 4μM) was added and fluorescence was recorded at 1-minute intervals for 1 hour (FLUOstar Omega plate reader) to monitor substrate proteolysis. Assays were repeated 3 times to obtain the mean fluorescence and ADAMTS13 activity was normalised to NHP, which was defined as 100%.
D-Dimer plasma levels
Plasma D-Dimer levels were quantified using an ELISA kit (ab196269, abcam, Cambridge, USA) according to the manufacturer's instructions. Plasma lithium heparin samples from CTEPH patients and healthy controls were used at a dilution of 1:1000.
Anti-ADAMTS13 autoantibodies
ADAMTS13 was immobilised directly on Maxisorp plates (Nunc) in carbonate buffer overnight at 4°C. After blocking with 1% BSA, patient plasma samples (1:10 dilution in 1% BSA) were applied to the plates for 1 hour. Bound antibodies were detected and quantified using a rabbit anti-human IgG polyclonal antibody conjugated with HRP. A standard curve of normal human plasma, containing known concentrations of the purified, patient derived anti-ADAMTS13 monoclonal antibody (II-1), was used as a positive control for the binding and detection of autoantibody [5] . Anti-ADAMTS13 autoantibodies were normalised to NHP, which was defined as 100%.
VWF multimeric size
VWF multimeric size was evaluated with a collagen binding assay (CBA) which utilises the increased collagen binding of higher multimeric VWF. Human type III placental collagen (5μg/mL) was immobilised in 96-well microplates plates (Nunc) in 50mM carbonate buffer, pH 9.6 at 4°C overnight. After washes with PBST, wells were blocked with 2% BSA in PBST for 1 hour. Plasma lithium heparin samples were diluted 1:100 in PBST 1% BSA and a standard curve of 0-1000ng/mL was made with NHP. VWF was detected with 1.1μg/mL polyclonal rabbit anti-human VWF/HRP (Dako) followed by plate development with OPD for 3 minutes. Collagen binding is reported as a ratio over the total plasma VWF antigen.
Clinical phenotype data
Phenotype data for the CTEPH, CTED and IPAH groups were recorded closest to the time of diagnosis and pre-operatively for the CTEPH and CTED patients undergoing PEA. This included demographics, haemodynamics, WHO functional class, 6-minute walk distance (6mwd), clinical blood tests, smoking history and anticoagulation therapy usage. Additionally, post-operative haemodynamics were recorded within 1 year of surgery for the CTEPH and CTED patients that underwent PEA, as part of routine care. Haemodynamics were evaluated by right heart catheterisation according to international guidelines and PEA was performed as previously described [6, 7] . The PE group had phenotype data recorded at a follow-up visit (median 220 days) after their acute PE, which also included a ventilation perfusion (VQ) scan to assess residual perfusion defects.
The relationship between the ADAMTS13-VWF axis and the amount of chronic thromboembolism was not evaluated as a validated radiological classification system does not exist.
Genotype data and genome-wide association study
To date, 1457 Caucasian CTEPH patients have been recruited from 8 European and US specialist pulmonary hypertension centres. The participating centres were: Each batch of micro-array intensity data was normalised, clustered and called independently using Illumina GenomeStudio [9] . Samples containing more than 1% of missing genotypes were removed and SNPs were then re-clustered to remove confounding from differential SNP exclusions between batches. SNPs with a low GenTrain score (<0.7) or clustering separation score (<0.5) were excluded [9, 10] .
Sample/SNP QC
Divergent ancestry was assessed using principal component analysis (PCA). Each batch was merged with the 1000 Genomes data using an intersecting set of SNPs [11] . A robust set of independent SNPs (n=30,609) was used for PCA, selected by the following criteria: genotype missingness < 5%, SNPs in Hardy-Weinberg equilibrium (HWE) (p>1x10 -5 ), minor allele frequency (MAF) > 5%, non-independent SNPs (pairwise R 2 < 0.2). Furthermore, SNPs in several regions with long-range linkage disequilibrium (LD) were excluded [12] . PCA against all populations in the 1000 genomes data was conducted and samples not clustering with European population were excluded. A second PCA was then performed with the remaining samples against European samples only, and outlying samples were also excluded. Thresholds were set by visual inspection of plots.
Additionally, individual samples were removed due to: outlying heterozygosity (3 standard deviations from the mean), duplicates or relatedness (Identity by descent > 0.1875) and missing genotypes (>1%; as described). SNP markers were removed due to: missing genotypes (>1%), deviation from HWE (p<1x10 -6 ), differential missingness rate between cases and controls (p<1x10 -5 ). and multi-allelic SNPs.
The 3 batches were then merged using an intersecting set of SNPs and further PCA was performed using the robust SNP set previously used for divergent ancestry quality control, to check for batch and recruiting centre effects.
Phasing/imputation
After quality control exclusions there were 1250 CTEPH cases, 1492 healthy controls and 915,999 SNPs. Phasing and imputation were performed using EAGLE 2 (v2.0.5) and positional Burrows-Wheeler transform (PBWT) software via the Sanger imputation service (https://imputation.sanger.ac.uk/) [13, 14] . The reference panel was the Haplotype Reference Consortium (release 1.1), containing 39 million biallelic SNPs from 32,470 individuals [15] . Following imputation, SNPs were excluded if they had a low minor allele frequency (<1%) or if they were poorly imputed (info score < 0.5), with 7,675,738 SNPs remaining for association testing.
208 CTEPH patients with ADAMTS/VWF antigen levels and 28 patients with CTED were also included in the CTEPH GWAS. Genotypes were available for 207 (187 CTEPH; 23 CTED) after GWAS quality control exclusions. Matched genotypes and ADAMTS / VWF antigen levels were not available for the healthy control, IPAH or PE groups.
Genetic ABO groups
The tagging SNPs used to reconstruct the genetic ABO groups A1, A2, B and O from phased haplotypes were: rs8176746, rs8176704, rs687289 and rs507666 [16] . The genetic ABO groups were compared to the available ABO antigen groups measured by serology (n=1490 Healthy control group) to confirm the accuracy of this method (98% concordance; n=29 were unable to be classified). The 10 genetic ABO groups were converted into A, B, AB and O groups using the following criteria: A = A1A1, A1A2, A2A2, A1O, A2O; B = BB, BO; AB = A1B, A2B; O = OO.
Protein quantitative trait loci
The post-imputation allelic dosages (0-2) of individual SNPs in the ADAMTS13 gene ± 40kb flanking region (n=396 variants) were tested against log transformed ADAMTS13 protein levels (dependent variable) and adjusted for age, sex and ADAMTS13 plasma antigen experimental batch. This region included the ADAMTS13 cis-pQTLs that have previously been described [17] [18] [19] . A Bonferroni p-value threshold <1.26x10 -4 (0.05/396 variants) was used to denote statistical significance. Partitioning of the variance explained by each variable within the models was performed by averaging over orders using the R package 'relaimpo' [20] .
Linkage disequilibrium was quantified from 1000 Genomes project data using LDlink (https://analysistools.nci.nih.gov/LDlink/, accessed 22/01/2018) in all European populations [21] .
Statistical analysis
The differences in categorical variables between groups were assessed using Chisquared or Fisher's exact test. The differences in continuous variables were assessed using the Mann-Whitney U test and the Kruskal-Wallis test.
Post-hoc pairwise diagnostic group comparisons were performed using Dunn's test with false discovery rate (FDR) adjustment for multiple testing. For matched values pre-and post-PEA Wilcoxon signed-rank test was used. P-values are reported to 3 decimal places and experimental data are reported to 3 significant figures. Data averages are described as median ± interquartile range unless specified.
Multivariable linear regression was performed using log-transformed ADAMTS13 or VWF protein levels as the dependent (outcome) variables after assessing log-likelihoods using the Box-Cox power transformation. Log-transformed ADAMTS13 and VWF were used in all multivariable linear regression models (supplementary tables S3, S4, S6, S7 and S8). Models were checked for normality of residuals, homoscedasticity and multicollinearity (variance inflation factor), with additional checks performed using the R package 'gvlma' [22] . We investigated interacting effects between the variables that were used in supplementary tables S4 and S5. The significant (p<0.05) and informative interactions were included in additional multivariable linear regression models (supplementary table S9 ).
Spearman's rank correlation coefficients were used to describe associations between ADAMTS13 or VWF protein levels and clinical phenotypes associated with disease severity (pulmonary vascular resistance (PVR), 6mwd and N-terminal pro b-type natriuretic peptide (NT-proBNP)) and blood markers of inflammation (white cell count (WCC), C-reactive protein (CRP), neutrophil and lymphocyte percentages). P-values from correlation testing were corrected for multiple testing using false discovery rate (FDR) adjustment.
Software
The analysis was performed using the following software: Illumina Genomestudio [9] , PLINK (v1.90beta) [23] , bcftools (v1.4.1) [24] , LDLink [21] , R (3.4.3) [25] and RStudio (1.1.414) [26] . The R packages used included: MASS [27] , coin [28] , gvlma [22] , PMCMR [29] , SNPRelate [30] , relaimpo [20] , jtools [31] , forestmodel [32] and the tidyverse suite [33] .
Supplementary Results

Data missingness
All individuals with CTEPH, CTED, PE, IPAH and healthy controls included in the analyses had ADAMTS13 and VWF antigen levels available (missingness: n=0/369, 0%).
The core variables used in multivariable linear models had the following missingness:
there was no missing data for age and sex (n=0/369, 0% missing) and ethnicity was missing in 7% (n=26/369). Data missingness for other variables are displayed in the figure and table legends. Analyses were performed using complete data. As missingness was low in core variables, imputation was not performed and is unlikely to have altered the results.
ADAMTS13 plasma concentrations
We were 95% powered to detect the difference in ADAMTS13 levels between CTEPH and healthy controls (healthy controls(n1)=68, CTEPH(n2)=208, effect size=0.5, twosided t-test of means) and 99% powered to detect the difference between the CTED group and healthy controls (healthy controls(n1)=68, CTED (n2)=35, effect size=1.12, two-sided t-test of means).
When the analysis is confined to batch 1 samples with a closer 1:1 matching between CTEPH (n=94) and healthy controls (n=68), the markedly reduced ADAMTS13 in the CTEPH group remains in a multivariable linear regression model (β (95% CI) (% change) 
ADAMTS13 activity, D-dimer, anti-ADAMTS13 autoantibodies and VWF multimeric size measurements
ADAMTS13 activity and D-dimer concentrations were measured in a subset of patients with CTEPH (n=23) with the lowest ADAMTS13 protein concentrations (below the 1st
Quartile of the CTEPH group) (0.556 ± 0.130 μg/mL) and compared to a subset of healthy controls (n=14, ADAMTS13: 1.03 ± 0.284 μg/mL).
ADAMTS13 activity
ADAMTS13 activity that is not adjusted for ADAMTS13 antigen levels is reduced (supplementary figure S10a). The increased specific ADAMTS13 activity (Act:Ag ratio) reflects the greater decrease in ADAMTS13:Ag compared to ADAMTS13:Act. Specific ADAMTS13 activity (Act:Ag) is not correlated with VWF:Ag in either CTEPH or healthy controls (supplementary figure S10b).
VWF multimeric size
The CTEPH (n=21) and healthy control subset (n=14) that were used to assess VWF multimeric size had a VWF plasma antigen level of 32.5 ± 6.80 μg/mL and 9.97 ± 4.99 μg/mL respectively. VWF:CBA was not correlated with ADAMTS13:Ag in CTEPH or healthy controls (supplementary figure S10c). VWF:CBA was correlated with VWF:Ag in healthy controls but not in CTEPH (supplementary figure S10d).
Clinical phenotype associations with ADAMTS13 and VWF
There were no correlations with blood markers of inflammation (CRP, WCC, neutrophil and lymphocyte %) (supplementary figure S5) . including when confining the analysis to samples that were taken on the same day as ADAMTS13 and VWF sampling (n=81, for WCC, neutrophil and lymphocyte %; n= 77 for CRP).
As proximal operable CTEPH has different risk associations to distal inoperable CTEPH and thus potentially different pathophysiological mechanisms we investigated the disease sub-types [34] . There was no difference in ADAMTS13 (p=0.070) or VWF (p=0.253) between the different sub-diagnostic categories of CTEPH (supplementary figures S11a and S11b). Furthermore, there was no difference in ADAMTS13 (p=0.366) or VWF (p=0.078) in those with and without post-operative residual pulmonary hypertension (mPAP  25mmHg) (n=83, 63%), which is a potential marker of distal vasculopathy (supplementary figures S11c and S11d) [35] .
CTEPH is a potential severe consequence of acute PE, however there are a spectrum of changes following PE (post-PE syndrome) that may have differing pathobiology [36] . We evaluated whether there was a difference in ADAMTS13 or VWF antigen levels depending on the degree of post-PE perfusion defects on available VQ scans (n=20). There was no difference in ADAMTS13 (p=0.812) or VWF (p=0.678) levels in those that had residual perfusion defects post-PE (n=12) compared with those with no perfusion defects (n=8) (supplementary figures S12a and S12b). Furthermore, there was no difference in ADAMTS13 (p=0.938) or VWF (p=0.427) levels when the PE group was stratified into provoked PE (n=8) and idiopathic PE (n=12) (supplementary figures S12c and S12d).
Dysregulation of the ADAMTS13-VWF axis is associated with stroke and myocardial infarction. Where co-morbidities were available for the CTEPH group, 5/74 (6%) had cerebrovascular disease and 20/124 (14%) had coronary artery disease. This is unlikely to have been a major confounder in the CTEPH group.
ABO groups and ADAMTS13-VWF
Reconstructing genetic ABO groups allowed us to explore more complex associations within the ABO subgroups. Whilst the A1 and A2 groups would be classified as non-O on serological testing, they have been associated with different effects on VWF levels and VTE risk [37] .
The small sample size of some non-O ABO groups (n: B=12, AB=13) limits the power to detect associations of smaller effect.
Protein quantitative trait loci for ADAMTS13
In a model adjusted for age, sex and batch, the lead SNP (rs3739893) explained 7.7% of the variance in ADAMTS13 levels within the CTEPH group (supplementary table S8 ).
However, as only 10 CTEPH patients had the rs3739893 effect allele, this accounts for a small proportion of the ADAMTS13 antigen level reduction observed in CTEPH.
The 4 other significantly associated SNPs were highly correlated with the lead SNP (R 2 =0.91-1.00, p<0.001). Additional analysis correcting for the first 5 ancestry informative principal components and VWF antigen levels did not alter the results.
In the linear regression model of ADAMTS13 antigen levels and rs3739893, the most variance in ADAMTS13 antigen levels was attributable to age (16%) (supplementary table S7), which is higher than reported in healthy cohorts [18] . In the CTEPH GWAS the effect allele frequency for rs3739893 was 0.0128 in CTEPH cases and 0.0158 in healthy controls and this was similar to a European (non-Finnish) reference population in gnomAD (0.0160) (http://gnomad.broadinstitute.org/, accessed Feb 2018). The results were unchanged when the analysis was confined to the CTEPH group.
Supplementary Figures
FIGURE S1
Flow chart of study design and study participant numbers. PEA (pulmonary endarterectomy), pQTL (protein quantitative trait loci). The number in each group are shown in bold. 
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FIGURE S2
The odds ratios of CTEPH in relation to healthy controls for combined ADAMTS13 and VWF groups. The ADAMTS13 and VWF group ORs are adjusted for age, sex, ethnicity and batch in a logistic regression model. N represents the total for both the CTEPH and healthy control groups. Threshold criteria and n (%) within the CTEPH and healthy control groups are shown in supplementary table S5. Forest plot generated with the R package 'forestmodel' [32] .
FIGURE S3
Anti-ADAMTS13 autoantibody percentage in CTEPH and healthy controls. Anti-ADAMTS13 autoantibodies were normalised to normal human control plasma, which was defined as 100%
FIGURE S4
Correlation of ADAMTS13 and VWF antigen levels with markers of disease severity in 
FIGURE S6
ADAMT13 and VWF antigen levels by comprehensive ABO genetic groups. The group differences were assessed using the Kruskal-Wallis test. Numbers in each group: OO = 51, A1A1 = 18, A1A2 = 11, A1B = 11, A1O = 81, A2A2 = 2, A2B = 2, A2O = 16, BB = 1, BO = 11.
FIGURE S7
Sample size calculations for ADAMTS13 plasma concentration. Sample sizes calculated from two samples using t-test of mean (R package `pwr`). a) Sample size estimation for a small-medium effect size. An estimated 142 individuals (per group) would be required for a small-medium effect size at a power of 80%.
b) Sample size estimation for large effect size (determined by pilot data) with unequal sample size (n: healthy controls 29, CTEPH 94).
n1/n2 (ratio of healthy controls to CTEPH), alpha (type 1 error probability), β (type 2 error probability).
FIGURE S8
Interaction effects for the multivariable linear model shown in supplementary table S9.
The predicted ADAMTS13 values are plotted with the interaction terms: a) Age:Diagnostic group. The ADAMTS13 difference between CTEPH patients and healthy controls is more pronounced for older patients than for younger patients.
ADAMTS13 levels remain lower in CTEPH patients across all ages compared with healthy controls. The rate of ADAMTS13 reduction in the CTED groups is similar to healthy controls and is also lower than healthy controls across all ages. b) Sex:Age. The rate of ADAMTS13 reduction with age is more pronounced for males than for females.
n=343 individuals included in the models.
FIGURE S9
Correlation of ADAMTS13 with VWF antigen levels in CTEPH (n=208) and healthy controls (n=68). Spearman's rank correlation in other diagnostic groups: CTED (rho = -0.161, p = 0.354), IPAH (rho = 0.329, p = 0.076), PE (rho = -0.0504, p = 0.799).
FIGURE S10
ADAMTS13 activity, D-dimer and VWF multimeric size in CTEPH and healthy controls.
Additional analysis using the data presented in figure 3 (See figure 3 for group details). a) Unadjusted ADAMTS13:Act (%) for CTEPH (84.4 ± 14.6 %) and healthy control (107 ± 13.5 %) groups. The Mann-Whitney U test was used to calculate group differences. Correlation was assessed with Spearman's rank correlation coefficients for both the healthy control (green circles) and the CTEPH (red triangles) groups (b, c, d).
FIGURE S11
ADAMTS13 and VWF antigen levels in CTEPH sub-diagnostic and post-PEA residual pulmonary hypertension groups. a) and b) ADAMTS13 and VWF antigen levels in CTEPH 
FIGURE S12
ADAMTS13 and VWF antigen levels in PE stratified by residual perfusion defects and provoked PE. The group differences were assessed using the Mann-Whitney U test.
Numbers in each group: no perfusion defect on VQ scan = 8, residual perfusion defect on VQ scan = 12, unprovoked (no VTE risk factors) = 12, provoked (VTE risk factors) = 8. Of those with residual perfusion defects, the majority were minor (n=10). (14) 19 (13) 19 (13) 9 (6) 9 (6) 48 (34) 14 (10) 8 ( 
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TABLE S7
Protein quantitative trait loci for ADAMTS13 antigen levels in CTEPH. Associations were assessed using multivariable linear regression and the SNPs included were those in the 
TABLE S10
ADAMTS13 antigen level quartiles for CTEPH and healthy controls. ADAMTS13 levels were divided by the median of the healthy control group and expressed as a percentage. The CTEPH group was then divided into quartiles (Q1-Q4) of the ADAMTS13 distribution of the healthy control group.
